Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of ELGN-2112 for intestinal malabsorption in preterm infants
MOH_2022-05-15_010783Phase 3Not yet recruiting
- Sponsor
- Elgan Pharma
- Start
- Apr 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in intestinal malabsorption comparing ELGN-2112 with Placebo (2 arms). Planned start Apr 2022; status: not yet recruiting.
02
Drugs
elgn-gi
03
Conditions
intestinal malabsorption
Beyond the preview
Go deeper on MOH_2022-05-15_010783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-05-15_010783.